XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

Pending FDA feedback, the Company will also seek FDA orphan drug designation (“ODD”) and NDA marketing approval for the XRx-026 program. Previously, oxypurinol was granted ODD for allopurinol ...

XORTX Therapeutics (XRTX) announces the launch of a new late stage program to treat gout. The new drug development program – XRx-026 – will ...

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

FOR centuries, gout has been a deeply misunderstood disease, associated only with jolly, indulgent, and often big men. When Henry VIII was diagnosed, it became firmly entrenched in popular belief ...

Now, phase 3 results with a new drug from Sobi and Selecta suggests ... current drugs like allopurinol and febuxostat aren’t able to achieve that objective, and there are estimated to be around ...

They’ll check your uric acid levels to diagnose your condition. Sometimes, they may prescribe a drug such as allopurinol (Zyloprim) or febuxostat (Uloric) to lower your uric acid levels.

But in the case of Zurampic (lesinurad) and Duzallo (lesinurad + allopurinol), sales have been ... in its entirety after market testing the drug and assessing results last month.

Attacks may be polyarticular and can intensify quickly. Colchicine in combination with probenecid or allopurinol is frequently used to treat gouty flares. [22] For acute attacks refractory to or ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...